Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
This study has been completed.
Study NCT00004132 Information provided by National Cancer Institute (NCI)
First Received: December 10, 1999 Last Updated: August 19, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Drug/Agent Toxicity by Tissue/Organ
Leukemia
Lymphoma
Oral Complications
Radiation Toxicity
Additional conditions recognized in this trial
Lymphoma, Large-Cell, Immunoblastic
Lymphoma, Non-Hodgkin
Multiple Myeloma
Neoplasms
Neoplasms, Plasma Cell
More general conditions related to this trial
Blood Protein Disorders
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Paraproteinemias
Vascular Diseases
Interventions listed in this trial
filgrastim
palifermin
cyclophosphamide
etoposide
ifosfamide
quality-of-life assessment
radiation therapy
Additional drug interventions recognized in this trial
Mitogens
More general drug interventions related to this trial
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Phytogenic
Antirheumatic Agents
Immunologic Factors
Immunosuppressive Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Back to top of Main Content
